Discovery of peliglitazar, a potent oxybenzylglycine dual PPARα/γ activator with efficacious glucose and lipid-lowering activities

被引：0

作者：

Chen, Sean ^{[1
]}

Qu, Fucheng ^{[1
]}

Devasthale, Pratik ^{[1
]}

Lai, Zhi ^{[1
]}

Shao, Chunning ^{[1
]}

Wang, Wei ^{[1
]}

Wu, Shung ^{[1
]}

Zhang, Hao ^{[1
]}

Farrelly, Dennis ^{[2
]}

Moore, Lisa ^{[2
]}

Gu, Liqun ^{[2
]}

Sun, Wei ^{[2
]}

Flynn, Neil ^{[2
]}

Harrity, Tom ^{[2
]}

Cap, Michael ^{[2
]}

Kunselman, Lori ^{[2
]}

Peters, Andrew ^{[2
]}

Locke, Ken ^{[3
]}

Lippy, Jonathan ^{[3
]}

Zhang, Litao ^{[3
]}

Chandrasena, Gamini ^{[4
]}

Hosagrahara, Vinayak ^{[4
]}

Kadiyala, Pathanjali ^{[4
]}

Muckelbauer, Jodi ^{[5
]}

Chen, Chiehying ^{[5
]}

An, Yongmi ^{[5
]}

Doweyko, Arthur ^{[6
]}

Ryono, Denis ^{[1
]}

Biller, Scott A. ^{[1
]}

Wetterau, John ^{[2
]}

Hariharan, Narayanan ^{[2
]}

Cheng, Peter T. W. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Discovery Chem, Princeton, NJ 08543 USA

[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Metab Dis Biol, Princeton, NJ 08543 USA

[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Lead Evaluat, Princeton, NJ 08543 USA

[4] Bristol Myers Squibb Co, Pharmaceut Res Inst, Preclin Candidate Optimizat, Princeton, NJ 08543 USA

[5] Bristol Myers Squibb Co, Pharmaceut Res Inst, Xray Crystallog, Princeton, NJ 08543 USA

[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, CADD, Princeton, NJ 08543 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

237-MEDI

引用

页码：788 / 788

页数：1

共 9 条

[1] MEDI 237-Discovery of peliglitazar, a potent oxybenzylglycine dual PPARα/γ activator with efficacious glucose and lipid-lowering activities
Thomas, Allen A.
Miller, Scott C.
Boyd, Steven A.
Condroski, Kevin
De Meese, Jason
Gunawardana, Indrani
Xu, Rui
Zhang, Gan
Lupher, Mark L., Jr.
Farouz, Francine S.
Jacobson, Irina
Staunton, Donald S.
Thorsett, Eugene D.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 904 - 904
[2] A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity
Brown, PJ
Winegar, DA
Plunket, KD
Moore, LB
Lewis, MC
Wilson, JG
Sundseth, SS
Koble, CS
Wu, ZD
Chapman, JM
Lehmann, JM
Kliewer, SA
Willson, TM
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (19) : 3785 - 3788
[3] Differences Between Rosuvastatin and Atorvastatin in Lipid-Lowering Action and Effect on Glucose Metabolism in Japanese Hypercholesterolemic Patients With Concurrent Diabetes - Lipid-Lowering With Highly Potent Statins in Hyperlipidemia With Type 2 Diabetes Patients (LISTEN) Study
Ogawa, Hisao
Matsui, Kunihiko
Saito, Yoshihiko
Sugiyama, Seigo
Jinnouchi, Hideaki
Sugawara, Masahiro
Masuda, Izuru
Mori, Hisao
Waki, Masako
Yoshiyama, Minoru
Watada, Hirotaka
CIRCULATION JOURNAL, 2014, 78 (10) : 2512 - 2515
[4] Aleglitazar, a balanced dual PPAR α/γ activator, exerts potent insulin-sensitizing and glucose-lowering effects in a nonhuman primate model of metabolic syndrome and type 2 diabetes mellitus
Hansen, B. C.
Tigno, X. T.
Benardeau, A.
Meyer, M.
Sebokova, E.
Mizrahi, J.
DIABETOLOGIA, 2009, 52 : S340 - S340
[5] BMS-298585, a novel uniquely balanced dual activator of PPAR alpha and gamma, shows robust glucose and lipid lowering effects in genetic and diet induced diabetic and hyperlipidemic mouse models
Hariharan, N
Sean, C
Cheng, P
Chu, C
Devasthale, P
Farrelly, D
Harrity, T
Selan, F
DIABETES, 2002, 51 : A100 - A100
[6] Discovery of ARRY-588, a novel glucokinase activator with potent glucose-lowering activity in animal models of type 2 diabetes mellitus
Aicher, Thomas
Boyd, Steven
Anderson, Debbie
Chicarelli, Mark
Condroski, Kevin
Dewolf, Walter, Jr.
Fell, Jay B.
Fischer, John
Galbraith, Sarah
Garrey, Rustai
Gunawardana, Indrani
Hinklin, Ronald
Hirsch, Jessica
Lee, Patrice
Neitzel, Nicolas
Pratt, Scott
Singh, Ajay
Sullivan, Francis
Turner, Timothy
Voegtli, Walter
Wallace, Eli
Williams, Lance
DIABETES, 2008, 57 : A139 - A139
[7] BMS-298585, a novel uniquely balanced dual activator of PPAR alpha and gamma, shows robust lipid and glucose lowering effects in high fat diet induced hyperlipidemic insulin resistant hamsters
Harrity, T
Hariharan, N
Cheng, P
Selan, F
Kunselman, L
Chen, S
Devasthale, P
Chu, C
Farrelly, D
DIABETES, 2002, 51 : A100 - A100
[8] Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation
Madrigal-Angulo, Jose Luis
Menez-Guerrero, Carlos
Estrada-Soto, Samuel
Jose Ramirez-Espinosa, Juan
Almanza-Perez, Julio Cesar
Leon-Rivera, Ismael
Hernandez-Nunez, Emanuel
Aguirre-Vidal, Yoshajandith
Flores-Leon, Carlos D.
Aguayo-Ortiz, Rodrigo
Navarrete-Vazquez, Gabriel
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 70
[9] Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities
Devasthale, PV
Chen, S
Jeon, Y
Qu, FC
Shao, CN
Wang, W
Zhang, H
Cap, M
Farrelly, D
Golla, R
Grover, G
Harrity, T
Ma, ZP
Moore, L
Ren, J
Seethala, R
Cheng, L
Sleph, P
Sun, W
Tieman, A
Wetterau, JR
Doweyko, A
Chandrasena, G
Chang, SY
Humphreys, WG
Sasseville, VG
Biller, SA
Ryono, DE
Selan, F
Hariharan, N
Cheng, PTW
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 2248 - 2250

← 1 →